Zafgen's Research into Weight Loss Drug, Beloranib, Looks Promising

Zafgen announced in November results of a completed Phase 2 study of their obesity drug, Beloranib, in severely obese patients (non-pws).  Findings from the study demonstrated significant weight loss in 147 obese individuals over a 12 weeks of treatment.
More recently, Zafgen shared results from a small trial involving 17 PWS adults. In the trial, the drug reduced weight and body fat as well as decreased the urge to food seek. Results from the Beloranib study have been reported in both the New York Times and Forbes magazine.

Topics: Research

Susan Hedstrom


Susan Hedstrom is the Executive Director for the Foundation for Prader-Willi Research. Passionate about finding treatments for PWS, Susan joined FPWR in 2009 shortly after her son, Jayden, was diagnosed with Prader-Willi Syndrome. Rather than accepting PWS as it has been defined, Susan has chosen to work with a team of pro-active and tireless individuals to accelerate PWS research in order to change the natural history of PWS. Inspired by her first FPWR conference and the team of researchers that were working to find answers for the syndrome, she hosted her first One SMALL Step walk in 2010 and began the development of the One SMALL Step walk program which now raises over $1.5 million a year for PWS research.